The assessment of effect of Rosuvastatin use on reduce of inflammatory markers in patients with venous thromboembolism

The assessment of effect of Rosuvastatin use on reduce of inflammatory markers including neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume and di-dimer in patients with venous thromboembolism

Two arm parallel group randomised trial with blinded postoperative care; phase 3. 220 patients are enrolled. Intervention group will receive standard treatment of vein thromboembolism and rosuvastatin (10 mg) for 3 months.

Both study groups (intervention and control) received anticoagulant therapy. In the intervention group, in addition, they receive rosuvastatin, 10 mg daily for 3 months Peripheral blood samples are taken to evaluate neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume and Di-dimer before treatment and 3 months later .

Patients diagnosed with venous thromboembolism, including deep vein thrombosis and pulmonary embolism without a history of inflammatory diseases such as rheumatic diseases , a history of blood diseases affecting neutrophils, lymphocytes and platelets, a history of regular use of anticoagulants or partial anticoagulant use in recent year , history of statin use, history of heart failure, history of liver disease, history of coagulopathy, previous history of venous thromboembolism, history of cancer and kidney patients undergoing dialysis

Patients will managed according to the standard treatment for vein thromboembolism. Intervention group will receive standard treatment for vein thromboembolism and rosuvastatin for 3 months . Control group will receive standard treatment for vein thromboembolism alone. All patients will followed-up in the outpatient clinic for 3 months.

Inflammatory complications of thrombotic disease such as post-thrombotic syndrome

Recruited patients are randomly allocated to either intervention or control arm. Both arms are in equal size. Randomization sequence is generated by Random Allocation Software version 1.0 May 2004, using a simple random method. It generates a randomization code for each participant (individual randomization). Randomization is run just one time at the beginning of the study. Then participants’ crossover based on the first randomized allocation. Sequentially numbered sealed opaque envelops are used to conceal the allocation. Each participant receives one envelope containing the randomization code.